<DOC>
	<DOCNO>NCT00173472</DOCNO>
	<brief_summary>The present project follow previous phaseⅡ study FOLFOX regimens treatment stage Ⅳ colorectal cancer . We recruit least 200 patient study . The selection patient base rigorous eligibility criterion . The patient allocate base expression molecular marker ( MSI , TS , DPD , MVD EGFR ) implementation chemotherapy . For example , examination clinical implication EGFR , patient classify four group : EGFR（＋） chemotherapy（＋） ; EGFR（＋） chemotherapy（－） ; EGFR（－） chemotherapy（＋） ; EGFR（－） chemotherapy（－） . Base analysis 2×2 table , clarify prognostic significance specific molecular marker due whether specific molecular marker predict biological invasiveness and/or chemosensitivity . We believe present study follow significance : （1）To clarify mechanisms carcinogenesis progression CRC ; （2）To facilitate development novel chemotherapeutic agent ; （3） To gain experience practice evidence-based medicine .</brief_summary>
	<brief_title>Association MSI , TS , DPD , MVD EGFR With Chemosensitivity Stage IV Colorectal Cancer</brief_title>
	<detailed_description>Stage IV disease represent approximately 25 % colorectal cancer ( CRC ) case . The mainstay treatment stage IV CRC chemotherapy surgery palliation symptom include colorectal bleeding obstruction . If patient stage IV CRC treat , average survival time 6 month . Recently , progress chemotherapeutic agent , oxaliplatin irinotecan , stage IV patient ’ average survival time considerably increase 18 month . However , currently utilize chemotherapeutic regimen , include FOLFOX ( Folinic acid ＋ 5-Fu ＋oxaliplatin ) FOLFIRI ( Folinic acid ＋ 5-Fu ＋ irinotecan ) , response rate around 50-60 % . Moreover , agent several severe side-effects , neurotoxicity diarrhea . Therefore , mandatory u seek clinicopathogical parameter novel molecular marker predict chemosensitivity , term increase response rate avoidance side-effects . Recently , carcinogenesis CRC well clarify . Some molecular marker , p53 , K-ras , microsatellite instability ( MSI ) , microvessel density（MVD） , epidermal growth factor receptor（EGFR） , relation survival colorectal cancer patient become focus research . The present project basically follow previous study p53 overexpression predict poor chemosensitivity（Liang et al . Int . J . Cancer 2002 ; 97 : 451-457） , plan explore association chemosensitivity MSI-H , MVD , EGFR . In fact , either FOLFOX FOLFIRI , belong 5-Fu-based therapy . Therefore , tumor expression enzymes related metabolism 5-Fu , thymidylate synthase（TS）and dipyrimidine dehydrogenase（DPD） , also become hot issue research . In project , explore clinical implication MSI , TS , DPD , MVD , EGFR . This previous study indicate MSI-H marker mutator phenotype colorectal cancer , i.e. , colorectal cancer MSI-H tend multiple mutation downstream gene , especially repetitive microsatellite sequence within gene . Our previous study show MSI-H predict good chemosensitivity（Liang et al . Int . J . Cancer 2002 ; 101 : 519-525） . Therefore , curious know MSI-H related alteration TS DPD tumor , i.e. , alteration tumor level TS DPD one mechanism well chemosensitivity tumor MSI-H. On hand , know EGFR related tumor growth , invasion , angiogenesis , metastasis colorectal cancer . Therefore , mandatory dissect correlation EGFR MVD . To best knowledge , publish . The present project follow previous phaseⅡ study FOLFOX regimens treatment stage Ⅳ colorectal cancer . We recruit least 200 patient study . The selection patient base rigorous eligibility criterion . The patient allocate base expression molecular marker implementation chemotherapy . For example , examination clinical implication EGFR , patient classify four group : EGFR（＋） chemotherapy（＋） ; EGFR（＋） chemotherapy（－） ; EGFR（－） chemotherapy（＋） ; EGFR（－） chemotherapy（－） . Base analysis 2×2 table , clarify prognostic significance specific molecular marker due whether specific molecular marker predict biological invasiveness and/or chemosensitivity . After analysis prognostic significance molecular marker , explore interrelationship molecular marker . Also , 5 molecular marker various clinicopathological factor subject multivariate analysis . Because survival stage Ⅳ CRC patient generally exceed 30 month , patient study follow long time final study result appear . We believe present study follow significance : （1）To clarify mechanisms carcinogenesis progression CRC ; （2）To facilitate development novel chemotherapeutic agent ; （3） To gain experience practice evidence-based medicine .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>The patient recruit meet follow eligibility criterion : ( 1 ) The sporadic primary colorectal cancer could palliatively resect pathologically confirm adenocarcinoma ; ( 2 ) The metastatic lesion measurable unresectable ; ( 3 ) Karnofsky performance status ≧50 % ; ( 4 ) The life expectancy great 12 week ; ( 5 ) WBC count ≧4,000/μL , platelet count ≧100,000/μL , serum bilirubin ≦2.0 mg/dL , serum glucose electrolyte normal . Patients evident family history colorectal cancer suggestive familial adenomatous polyposis ( FAP ) hereditary nonpolyposis colorectal cancer ( HNPCC ) exclude study . Moreover , patient evident carcinosis peritonitis exclude study bowel function could restore palliative operation prognosis consider poor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>colorectal cancer , MSI , TS , DPD , EGFR , chemotherapy .</keyword>
</DOC>